Granulocyte-macrophage colony-stimulating factor: an immunotarget for sepsis and COVID-19

[1]  C. Libertin,et al.  GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia , 2020, Mayo Clinic Proceedings.

[2]  E. Audureau,et al.  Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome , 2020, American journal of respiratory and critical care medicine.

[3]  A. Zangrillo,et al.  GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study , 2020, The Lancet Rheumatology.

[4]  J. Isaacs,et al.  Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities , 2020, The Lancet Respiratory Medicine.

[5]  Zheng Zhang,et al.  High levels of circulating GM-CSF+CD4+ T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study , 2018, Cellular & Molecular Immunology.

[6]  Zheng Zhang,et al.  High levels of circulating GM-CSF+CD4+ T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study , 2018, Cellular & Molecular Immunology.

[7]  Burkhard Becher,et al.  GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation. , 2016, Immunity.

[8]  Fan Yang,et al.  STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation , 2014, Cell Research.

[9]  L. Moldawer,et al.  Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care , 2012, The journal of trauma and acute care surgery.

[10]  F. Safavi,et al.  The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF , 2011, Nature Immunology.

[11]  J. Carcillo,et al.  Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome , 2011, Intensive Care Medicine.

[12]  T. Baumann,et al.  Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. , 2009, American journal of respiratory and critical care medicine.

[13]  J. Carcillo.  Critical Illness Stress-induced Immune Suppression , 2007, Intensive Care Medicine.

[14]  John W. Wilson,et al.  A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. , 2002, American journal of respiratory and critical care medicine.

[15]  M. Williams,et al.  Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. , 1998, The Journal of infectious diseases.

[16]  G. Dranoff,et al.  Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. , 1994, Science.